TITLE

Research Update

PUB. DATE
October 2007
SOURCE
PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug testing. Nventa Biopharmaceuticals Corp. has started its Phase I trial to determine the safety of therapeutic vaccine for patients with intraepithelial neoplasia.
ACCESSION #
26926489

 

Related Articles

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Oct2007, Vol. 6 Issue 10, p8 

    The article reports that Nventa Biopharmaceuticals Corp. has started a Phase I trial which evaluates the safeness and tolerability of its therapeutic vaccine in patients with cervical intraepithelial neoplasia (CIN) in the U.S. It also aims to assess T-cell and B-cell specific HPV-E7 immune...

  • Sinovac: Panflu on track in pandemic flu.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p38 

    The article reports on the completion of Sinovac Biotech Ltd.'s phase I clinical trial of its avian influenza vaccine Panflu on the shot regimen of either the vaccine or placebo. The action represents another step on the product candidate's way to becoming a much-needed addition to global...

  • SINOVAC BIOTECH SUBMITS CLINICAL TRIAL APPLICATION FOR PCV.  // Worldwide Biotech;Apr2011, Vol. 23 Issue 4, p4 

    The article reports the clinical trial application of biopharmaceutical firm Sinovac Biotech Ltd. for its 13-valent pneumococcal conjugate vaccine (PCV) to the State Food and Drug Administration (SFDA) of China. The vaccine regulatory system of the SFDA passed the evaluation of the World Health...

  • Sinovac Jumps on Results for Hand, Foot and Mouth Vaccine. Shaffer, Catherine // BioWorld Today;3/15/2013, Vol. 24 Issue 50, p1 

    The article discusses the results of the Phase III data of the double-blind, randomized, placebo-controlled trial of Sinovac Biotech Ltd.'s enterovirus 7I (EV 7I) vaccine which reveal efficacy, immunogenicity and safety against hand, foot and mouth disease (HFMD). The data showed a 95.4 percent...

  • SINOVAC GETS SFDA APPROVAL TO BEGIN EV71 VACCINE TRIALS.  // Worldwide Biotech;Feb2011, Vol. 23 Issue 2, p5 

    The article reports on an approval received by Sinovac Biotech Ltd. from the China State Food and Drug Administration (SFDA) to begin clinical trials for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD). Majority of HFMD cases happen in children under five...

  • VACCINE REPORT.  // BioPharm International;Feb2008, Vol. 21 Issue 2, p12 

    The article offers news briefs related to vaccine developments. Apitope Technology Ltd. launched ATX-MS-1467, a therapeutic vaccine, which is safe for secondary progressive multiple sclerosis (SPMS) patients. Sinovac Biotech Ltd. conducted a positive clinical trial of pandemic influenza (H5N1)...

  • Sinovac: Panflu on track in pandemic flu.  // PharmaWatch: Biotechnology;May2006, Vol. 5 Issue 5, p5 

    The article reports on the completion of the immunization schedule in the phase I pandemic influenza vaccine trial of Sinovac Biotech Co. Ltd. in 2006. The company has announced that all 120 volunteers in a phase I clinical trial of its avian influenza vaccine Panflu have completed the two-shot...

  • Sinovac Biotech conducts world's first human clinical testing of SARS vaccine.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p6 

    Reports on Sinovac Biotech Ltd.'s commencement of phase I human clinical trials of SARS vaccine in China. Number of patients included in the study; Response of subject receiving SARS vaccine; Support received by the company from the U.S. National Institute of Health.

  • SINOVAC DEVELOPING VACCINE FOR HAND, FOOT, AND MOUTH DISEASE.  // Worldwide Biotech;Nov2008, Vol. 20 Issue 11, p2 

    The article reports that Chinese vaccines developer Sinovac Biotech Ltd. has initiated the development of a vaccine human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD). Sinovac will be supplied with epidemiology study results from the outbreak area to facilitate its...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics